

Claims

1. Use of a compound of formula I:

5 $\text{RC(O)-NH-(CH}_2\text{)}_n\text{-CH=CH}_2$
 wherein R represents C_{1-20} alkyl, C_{2-20} alkenyl or C_{2-20} alkynyl; and
 n is an integer from 0 to 3,

 in the manufacture of a medicament for use in pain relief.

10

2. A compound of formula I as defined in claim 1 for use in medicine.

3. A method of providing pain relief to a patient comprising
administering to said patient an effective amount of a compound of
15 formula I, as defined in claim 1.

4. Use according to claim 1 or method according to claim 3 wherein the
medicament further comprises one or more analgesics or the patient
is administered said further one or more analgesics.

20

5. The use, compound or method of any of the previous claims wherein,
in the compound of formula I, R represents C_{10-20} alkyl, C_{10-20} alkenyl
or C_{10-20} alkynyl.

25 6. The use, compound or method of any of claims 1 to 4 wherein, in the
compound of formula I, R represents C_{10-20} *n*-alkyl, C_{10-20} mono-
alkenyl or C_{10-20} mono-alkynyl.

7. The use, compound or method of any of claims 1 to 4 wherein, in the compound of formula I, R represents C₁₀₋₂₀ *n*-alkyl, C₁₀₋₂₀ mono-*n*-alkenyl or C₁₀₋₂₀ mono-*n*-alkynyl.
- 5 8. The use, compound or method of any of claims 1 to 4 wherein, in the compound of formula I, R represents C₁₁₋₁₉ *n*-alkyl, or C₁₁₋₁₉ mono-*n*-alkenyl.
9. The use, compound or method of any of claims 1 to 4 wherein, in the
10 compound of formula I, R represents C₁₁₋₁₈ *n*-alkyl, or C₁₁₋₁₈ mono-*n*-alkenyl.
10. The use, compound or method of any of claims 1 to 4 wherein, in the
15 compound of formula I, the alkenyl or alkynyl groups have no more than 3 C-C double or triple bonds, respectively.
11. The use, compound or method of any of claims 1 to 5 wherein the compound is not *N*-(2-propenyl) – 5,8,11,14-eicosatetraenamide.
- 20 12. The use, compound or method of any of the previous claims wherein, in the compound of formula I, *n* represents 0 or 1.
13. The use, compound or method of claim 12 wherein, in the compound of formula I, *n* represents 1
25
14. The use, compound or method of any of claims 1 to 4 wherein the compound is *N*-(2-propenyl) hexadecanamide, *N*-(2-propenyl) cis-9-octadecanamide, *N*-(2-propenyl) cis-9-hexadecanamide, *N*-(2-propenyl) tetradecanamide, *N*-(2-propenyl) cis-9-tetradecanamide, *N*-(2-propenyl) octadecanamide, *N*-(2-propenyl) trans-9-
30

octadecenamide, *N*-(2-propenyl) dodecanamide, or *N*-(2-propenyl) cis-5-dodecenamide.

15. A use compound or method of any of the previous claims wherein
5 the compound is *N*-(2-propenyl) hexadecanamide.
16. A pharmaceutical composition comprising a compound as defined in
relation to any of the previous claims and one or more analgesics and
a pharmaceutically acceptable excipient.
- 10 17. A kit of parts comprising:
- (a) a compound as defined in relation to any of the previous claims;
and,
15 (b) one or more analgesics; and,
(c) a pharmaceutically acceptable excipient
18. A use or method according to claim 4 or pharmaceutical composition
according to claim 16 or a kit of parts according to claim 17 wherein
20 the analgesic is an opioid, a non-steroidal anti-inflammatory drug, a
local anaesthetic, a NMDA receptor antagonist, a cannabinoid, an
antidepressant, and/or an anticonvulsant.
- 25